Sientra (NASDAQ:SIEN) and Wound Management Technologies (OTCMKTS:WNDM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.
Institutional & Insider Ownership
87.0% of Sientra shares are owned by institutional investors. 31.0% of Sientra shares are owned by company insiders. Comparatively, 9.6% of Wound Management Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a summary of current ratings and price targets for Sientra and Wound Management Technologies, as provided by MarketBeat.
Sientra presently has a consensus target price of $24.14, suggesting a potential upside of 64.01%. Given Sientra’s higher probable upside, research analysts clearly believe Sientra is more favorable than Wound Management Technologies.
Risk and Volatility
Sientra has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500. Comparatively, Wound Management Technologies has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.
This table compares Sientra and Wound Management Technologies’ net margins, return on equity and return on assets.
Earnings and Valuation
This table compares Sientra and Wound Management Technologies’ top-line revenue, earnings per share and valuation.
Wound Management Technologies has lower revenue, but higher earnings than Sientra.
Sientra beats Wound Management Technologies on 6 of the 11 factors compared between the two stocks.
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. It also provides body contouring products; facial and nasal implants; saline-filled breast implant sizers to identify the correct style and size of implants; and non-breast tissue expanders for expanding tissue and skin surface area for burn care and other reconstructive use. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.
About Wound Management Technologies
WNDM Medical Inc. develops, markets, and distributes biotechnology products to physicians, hospitals, and clinics in the United States. The company offers HemaQuell, a resorbable bone hemostat for bone healing; and CellerateRX surgical for healing. The company was formerly known as Wound Management Technologies, Inc. and changed its name to WNDM Medical Inc. in April 2017. WNDM Medical Inc. was founded in 1982 and is based in Fort Worth, Texas.